We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Read MoreHide Full Article
The latest trading session saw Novo Nordisk (NVO - Free Report) ending at $116.47, denoting a -0.73% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a loss of 0.05% for the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.18%.
The drugmaker's stock has dropped by 5.15% in the past month, falling short of the Medical sector's loss of 4.16% and the S&P 500's gain of 2.76%.
Market participants will be closely following the financial results of Novo Nordisk in its upcoming release. The company plans to announce its earnings on November 6, 2024. The company is forecasted to report an EPS of $0.90, showcasing a 23.29% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $10.69 billion, indicating a 24.59% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $3.07 per share and a revenue of $42 billion, demonstrating changes of +13.7% and +24.6%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.01% decrease. Novo Nordisk currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 38.27. This indicates a premium in contrast to its industry's Forward P/E of 15.88.
Also, we should mention that NVO has a PEG ratio of 1.51. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.61 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 30, finds itself in the top 12% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
The latest trading session saw Novo Nordisk (NVO - Free Report) ending at $116.47, denoting a -0.73% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a loss of 0.05% for the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.18%.
The drugmaker's stock has dropped by 5.15% in the past month, falling short of the Medical sector's loss of 4.16% and the S&P 500's gain of 2.76%.
Market participants will be closely following the financial results of Novo Nordisk in its upcoming release. The company plans to announce its earnings on November 6, 2024. The company is forecasted to report an EPS of $0.90, showcasing a 23.29% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $10.69 billion, indicating a 24.59% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $3.07 per share and a revenue of $42 billion, demonstrating changes of +13.7% and +24.6%, respectively, from the preceding year.
It is also important to note the recent changes to analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 3.01% decrease. Novo Nordisk currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 38.27. This indicates a premium in contrast to its industry's Forward P/E of 15.88.
Also, we should mention that NVO has a PEG ratio of 1.51. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.61 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 30, finds itself in the top 12% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.